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Stability-indicating liquid chromatographic and UV 
spectrophotometric methods for the quantification of ciprofibrate 
in capsules and tablets
Fernanda Macke Hellwig, Rafael Henrique Dias Reis, Suzana Del Rosso Barbosa, Marcelo Donadel 
Malesuik*
School of Pharmacy, Federal University of Pampa, UNIPAMPA, Uruguaiana, RS, Brazil
This study describes the development and evaluation of stability-indicating liquid chromatographic 
(LC) and UV spectrophotometric methods for the quantification of ciprofibrate (CPF) in tablets and 
capsules. Isocratic LC separation was achieved on a RP18 column using a mobile phase of o-phosphoric 
acid (0.1% v/v), adjusted to pH 3.0 with triethylamine (10% v/v) and acetonitrile (35:65 v/v), with a 
flow rate of 1.0 mL min-1. Detection was achieved with a photodiode array detector at 233 nm. For the 
spectrophotometric analysis, ethanol and water were used as the solvent and a wavelength of 233 nm 
was selected for the detection. The methods were validated according to International Conference on 
Harmonization (ICH) guidelines for validating analytical procedures. Statistical analysis showed no 
significant difference between the results obtained by the two methods. The proposed methods were 
successfully applied to the CPF quality-control analysis of tablets and capsules.
Uniterms: Ciprofibrate/tablets/quality control. Ciprofibrate/capsules/quality control. UV 
Spectrophotometry/quantitative analysis. Liquid chromatography/stability study. Medicines/quality 
control.
Este estudo descreve o desenvolvimento e avaliação de método indicativo da estabilidade por 
cromatografia líquida (LC) e método por espectrofotometria UV para quantificação de ciprofibrato 
(CPF) em comprimidos e cápsulas. No método por cromatografia líquida as análises foram realizadas 
isocraticamente em coluna de fase reversa C18, utilizando fase móvel composta por ácido o-fosfórico 
(0.1% v/v) pH 3.0, ajustado com trietilamina (10% v/v), e acetonitrila (35:65 v/v), com fluxo de 1,0 mL 
min-1. A detecção foi realizada em detector de arranjo de diodos a 233 nm. Na análise espectrofotométrica, 
etanol e água foram utilizados como solventes e o comprimento de onda de 233 nm foi selecionado 
para a detecção do fármaco. Os métodos foram validados de acordo com as diretrizes do International 
Conference on Harmonization (ICH). A análise estatística não mostrou diferença significativa entre os 
resultados obtidos pelos dois métodos. Os métodos foram aplicados com sucesso para análises de controle 
de qualidade do ciprofibrato em comprimidos e cápsulas.
Unitermos: Ciprofibrato/comprimidos/controle de qualidade. Ciprofibrato/cápsulas/controle de qualidade. 
Espectrofotometria UV/análise quantitativa. Cromatografia líquida/estudo da estabilidade. Medicamentos/
controle de qualidade.
INTRODUCTION
Ciprofibrate (CPF, Figure 1) is a hypolipidemic 
drug that is widely used to treat hypertriglyceridemia. 
Its chemical name is 2-(4-(2,2-dichlorocyclopropyl) 
phenoxy)-2-methylpropanoic acid and its mechanism of 
action is based on the activation of specific transcription 
factors called peroxisome proliferator-activated receptors 
(PPARs), which alter the transcription of several genes that 
encode the proteins that control lipoprotein metabolism 
(Bighetti et al., 2009; Bermúdez-Pirela et al., 2005; 
European Pharmacopeia, 2008).
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CPF is commercially available as both tablets 
and capsules (100 mg). An official method for the 
determination of this drug in oral formulations has not yet 
been described. Publications concerning the quantitative 
detection of CPF are relatively limited. However, there are 
studies describing the quantification of this drug in bulk 
and tablet forms by UV and visible spectrophotometry 
(Nascimento et al., 2011), high-performance thin-layer 
chromatography (HPTLC) (Jain et al., 2011) and LC–
UV (Jain et al., 2012); LC/MS/MS has also been used 
to quantify CPF in human plasma (Mendes et al., 2011). 
Several of these methods present methodologies based on 
techniques with high sensitivity and accuracy, but they 
require the use of hazardous and expensive chemicals, 
which make the process not only dangerous for the 
environment but also complex and time consuming. 
Moreover, there are no publications concerning UV 
spectrophotometric or stability-indicating LC methods for 
the quantification of CPF in capsules and tablets, and there 
is also no comparison study of the two methods.
The aim of this study was to develop and validate a 
simple stability-indicating LC method and a simple, fast 
and environmentally friendly UV spectrophotometric 
method for routine CPF analysis in tablets and capsules. 
The results obtained by these methods were statistically 
compared using two one-sided test (TOST). In addition, 
the reliability and feasibility of the results were evaluated, 
focusing on routine quality-control analysis.
MATERIAL AND METHODS
Chemicals and reagents
The CPF reference substance (Purity Grade 
Standards, Durham, USA) was kindly provided by 
Multilab (São Jerônimo, Brazil). The pharmaceutical 
formulations, capsules and tablets containing CPF were 
obtained commercially. The tablets were labelled as 
containing 100 mg of CPF and the following inactive 
ingredients: starch, microcrystalline cellulose, silicon 
dioxide, hypromellose, lactose monohydrate, sodium 
lauryl sulfate, hydrogenated vegetable oil and purified 
water. The capsules were labelled as containing 100 mg 
of CPF and the following inactive ingredients: magnesium 
stearate, silicon dioxide, microcrystalline cellulose and 
starch.
LC-grade acetonitrile was purchased from J. T. 
Baker (USA) and analytical-grade ethanol was obtained 
from Fmaia (Brazil). All of the chemicals used were of 
pharmaceutical or analytical grade. All aqueous solutions 
were prepared with purified water, obtained using Milli-Q 
apparatus (Millipore®).
LC method
Development
The chromatographic conditions were optimised so 
that the performance of the assay was high. In order to find 
the most appropriate mobile phase for CPF determination, 
different solvent mixtures were analysed. Acetonitrile 
and methanol are organic solvents commonly used in 
LC; therefore, various mixtures of acetonitrile, methanol, 
water and o-phosphoric acid (0.1% v/v) were tested. 
Before mixing with an organic solvent, the pH value of 
the o-phosphoric acid was checked over the range pH 
2.0–5.0. Different ratios of organic and aqueous phases 
were used to obtain the best analysis time and system 
suitability parameters. System suitability testing of the 
chromatographic system was performed before each 
validation run using five replicate injections of a standard 
solution. The number of theoretical plates, tailing factor, 
and injection repeatability were determined.
Instrumentation and conditions
The LC system consisted of a Shimadzu® instrument 
equipped with a diode array detector (DAD). The 
separation was performed using a Shimadzu® Shim-pack 
CLS-ODS (M) column (250 mm x 4.6 mm, internal 
diameter: 5 μm) at room temperature, eluted at the flow 
rate of 1.0 mL min-1 with an injection volume of 20 μL, 
using an isocratic system. The mobile phase consisted of 
o-phosphoric acid (0.1% v/v) that was adjusted to pH 3.0 
using triethylamine (10% v/v) and acetonitrile (35:65 v/v). 
The detection of CPF was achieved with a photodiode 
array detector at 233 nm. The mobile phase was filtered 
through a 0.45 µm-thick nylon filter and degassed in an 
ultrasonic bath before use. The data obtained showed that 
the mobile phase was stable for at least 48 h when stored 
in a closed flask at room temperature.
Calibration solutions
A CPF stock solution with a concentration of 
FIGURE 1 - Chemical structure of CPF (European Pharmacopeia 
6th Ed, 2008).
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500 μg mL-1 was prepared in a volumetric flask by 
dissolving the CPF reference substance (12.5 mg) in 
ethanol (10 mL) and making it up to a volume of 25 mL 
with purified water. Aliquots of 1, 1.5, 2, 2.5 and 3 mL 
were transferred to several volumetric flasks and diluted 
with purified water to produce final concentrations of 10, 
15, 20, 25 and 30 μg mL-1.
Sample preparation solutions
The average weight of 20 tablets and 20 capsules 
was determined according to the Farmacopeia Brasileira 
(2010). The tablets were crushed to form a homogeneous 
powder and the contents of the capsules were homogenised. 
An accurately weighed amount of powder, equivalent to 
12.5 mg CPF, was transferred to a 25 mL volumetric flask, 
extracted with ethanol (10 mL), sonicated for 5 min, and 
diluted to the 25 mL mark by adding water. An aliquot 
of this solution (2 mL) was transferred into a 50 mL 
volumetric flask, which was diluted with water to give 
a final concentration of 20 μg mL-1. The solutions were 
filtered through a 0.45 μm-thick nylon filter before LC 
analysis.
UV spectrophotometric method
Development
Different solvent media were investigated to 
develop a suitable UV spectrophotometric method for 
the analysis of CPF in formulations. In order to select the 
appropriate media, various criteria were used, including 
sensitivity of the method, ease of sample preparation, 
solubility of the drug, time consumption and cost of the 
solvents. The concentration and absorbance of CPF in the 
selected medium at the associated wavelengths were also 
determined.
Instrumentation and conditions
Spectral and absorbance measurements were 
performed on a Perkin Elmer Lambda 35 UV/Vis 
spectrophotometer, using quartz cells with a 1.0 cm path 
length and detection at 233 nm.
Calibration solutions
A CPF stock solution with a concentration of 
400 μg mL-1 was prepared in a volumetric flask by 
dissolving the CPF reference substance (10 mg) in ethanol 
(10 mL) and making it up to a volume of 25 mL with 
purified water. Aliquots of 1, 1.5, 2, 2.5 and 3 mL were 
transferred to several volumetric flasks and diluted with 
purified water to produce final concentrations of 8, 12, 16, 
20 and 24 μg mL-1.
Sample preparation for the solutions
The average weight of 20 tablets and 20 capsules 
was determined according to the Farmacopeia Brasileira 
(2010). The tablets were crushed to form a homogeneous 
powder and the contents of the capsules were homogenised. 
An accurately weighed amount of powder, equivalent to 
10 mg CPF, was transferred to a 25 mL volumetric flask, 
extracted with ethanol (10 mL), sonicated for 5 min, and 
diluted to the 25 mL mark by adding water. After filtration, 
an aliquot (2 mL) of this solution was transferred into a 
50 mL volumetric flask and diluted with water to give a 
final concentration of 16 μg mL-1.
Method validation
The developed stability-indicating LC and UV 
spectrophotometric analytical methods were validated 
following ICH guidelines and USP requirements 
(International Conference on Harmonization, 2005; United 
States Pharmacopeia, 2012).
Linearity
The linearity was evaluated by linear regression 
analysis, which was calculated using the least-square 
regression method. The calibration curves were obtained 
with five concentrations for LC (10-30 μg mL-1) and UV 
methods (8-24 μg mL-1).
Specificity
The UV method was performed by preparing 
placebo solutions (an in-house mixture of tablet and 
capsules excipients) of the commercial products. In 
a separate study, a CPF reference substance with the 
same concentration was prepared and analysed. Each 
of the solutions was scanned from a wavelength of 400 
to 200 nm, and any interference in the absorbance was 
checked at all tested wavelengths.
In order to establish if the proposed LC method 
was in fact stability indicating, the pure CPF active 
pharmaceutical ingredient was stressed under different 
conditions as part of the forced degradation studies 
(Bakshi, Singh, 2002).
The CPF solutions for acid hydrolysis were 
prepared by dissolving the drug in a small volume of 
ethanol and diluting with aqueous hydrochloric acid to 
achieve a concentration of 1 mg mL-1. Acid hydrolysis 
was performed in 1 M HCl at 80 °C for 4 h under reflux, 
after which the sample was cooled to room temperature 
and neutralised. The study under alkaline conditions was 
carried out in 1 M NaOH at 80 °C for 7 h under reflux, 
after which the sample was cooled to room temperature 
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and neutralised. An aliquot of each solution was diluted 
with water to give a final concentration of 20 µg mL -1. 
The stress degradation study with direct UV radiation 
(254 nm) was performed by exposing the CPF solution in 
acetonitrile (1 mg mL-1) to the UV beam for 1.5 h at room 
temperature in a photostability chamber containing mirrors 
(Malesuik et al., 2009; Garcia et al., 2008). The distance 
between the lamp and the sample was 10 cm. Afterwards, 
the solution was diluted to a concentration of 20 µg mL-1 
with water. Samples subjected to identical conditions, 
but protected from light, were used as a control. The 
oxidative reaction was performed by dissolving CPF in a 
small volume of ethanol and then diluting with 30% H2O2 
(1 mg mL-1) at 80°C for 3 h under reflux. An aliquot of this 
solution was diluted in water to give a final concentration 
of 20 µg mL-1. To verify the stability of the CPF solution 
in anhydrous ethanol and water, the samples were prepared 
and analysed after they had been stored for 2, 6, 8 and 24 h 
at room temperature.
Peak purity tests were performed by the photodiode 
array detector, which were useful to show that the analyte 
chromatographic peak did not contain more than one 
substance.
Precision
The precision of the methods was evaluated by 
repeatability (intra-day precision) and intermediate 
precision (inter-day precision) tests. The repeatability was 
tested by assaying six samples at the same concentration 
(20 µg mL-1) throughout one day under consistent 
experimental conditions. The intermediate precision of 
the method was assessed by carrying out the analysis 
on three different days and with a different analyst 
performing the analysis in the same laboratory (between-
analyst precision). Data were expressed as a function 
of the relative standard deviation (RSD%) of a series of 
measurements.
Accuracy
The accuracy was determined by a recovery test, 
which consisted of adding aliquots of 1.0, 2.0 and 3.0 mL 
of the standard CPF solution (LC and UV stock solutions) 
to placebo solutions, which gave final concentrations of 
the reference standards as 10, 20 and 30 μg mL-1 for LC 
and 8, 16 and 24 μg mL-1 for UV tests. Each solution was 
prepared in triplicate.
Robustness
The robustness of the UV method was evaluated 
by analysing the same samples with small and deliberate 
modifications to the analytical conditions, such as 
changing the sonication time (3 and 7 min), amount of 
added organic solvent (8 and 15 mL ethanol), manufacturer 
of the organic solvent and the stability of the CPF solutions 
for 24 hours at room temperature.
The robustness of the LC method was determined 
by analysing the same samples but with different method 
parameters, such as pH of the mobile phase (± 0.2 units), 
the flow rate (± 0.2 mL min-1), proportion of each solvent 
in the mobile phase (± 5% organic phase) and the column 
(with the same specification, but acquired from a different 
supplier).
RESULTS AND DISCUSSION
LC method development and optimisation
The development of a LC method requires the 
careful consideration of the polarity of the analyte, 
stationary phase and mobile phase in order to obtain 
good separation within a reasonable time. Thus, the LC 
procedure was optimised to develop a stability-indicating 
method so that the degradation products from the drug 
could be resolved. The chromatographic conditions were 
chosen after testing different mobile phases with different 
proportions of organic and aqueous solvents (Figures 2 
and 3). Acetonitrile and methanol are commonly used 
solvents in reverse-phase LC, because they have low UV 
cut-off points of 190 and 205 nm, respectively. These 
solvents are miscible with aqueous solutions, so reverse-
phase chromatography was performed with various 
mixtures of organic and aqueous solvents. During the 
development phase, acetonitrile and methanol were used 
in the mobile phase at different ratios, which resulted 
in an asymmetric peak with a large tailing factor (T >2) 
and a very low retention time (Figure 2f). Exchanging 
methanol with water did not improve the separation, 
and the peak was still unresolved from the void volume 
(Figure 2e). To achieve a better separation, the aqueous 
phase and pH (in the range 2.0–5.0) were changed to 
optimise the CPF retention time to 6 min (Figures 2a, 
b, c and d). Different ratios of the organic phase were 
analysed (Figure 3). Finally, a mobile phase containing 
o-phosphoric acid (0.1% v/v), adjusted to pH 3.0 by 
adding triethylamine (10% v/v) and acetonitrile (35:65 
v/v), was adopted because of its low tailing factor, good 
capacity factor (k´) value, retention time and its ability to 
separate the degradation products from CPF with good 
peak parameters (Figure 5). The pH value of 3.0 was 
chosen because it showed a better peak profile compared 
those obtained at pH 4 and 5, and a pH value as low as 
2.0 could damage the column.
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FIGURE 2. Chromatograms of CPF standard solution in tested mobile phases with 65% of ACN and 35% of a) o-phosphoric acid 
0.1% (v/v) pH 5.0, b) o-phosphoric acid 0.1% (v/v) pH 4.0, c) o-phosphoric acid 0.1% (v/v) pH 3.0, d) o-phosphoric acid 0.1% 
(v/v) pH 2.0, e) purified water and f) methanol.
FIGURE 3. Chromatograms of CPF standard solution using as mobile phase ACN and o-phosphoric acid 0.1% (v/v) pH 3.0 in 
different ratios: a) 80:20; b) 65:35 and c) 50:50.
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A system suitability test of the chromatographic 
system was performed before each validation run. The 
system suitability test is an integrated part of the analytical 
method, which ascertains the suitability and effectiveness 
of the operating system. It was carried out to evaluate 
the reliability and reproducibility of the system for the 
analysis, using five replicate injections of a reference 
solution containing 20 µg mL-1 CPF. The approximate 
results gave the following results: theoretical plates 
(N = 6800), tailing factor or peak asymmetry (T = 1.2) and 
injection repeatability (RSD% = 0.36, n = 5). The values 
for these parameters were satisfactory and in accordance 
with previously published data (Shabir, 2003). The tests 
ensure that the LC method generates reliable results. Thus, 
it was established that the LC system and procedure are 
capable of providing data of an acceptable quality.
UV method development and optimisation
In this study, different solvents were investigated to 
develop a suitable UV spectrophotometric method for the 
analysis of CPF in tablets and capsules. For the selection 
of diluents, the criteria employed were the sensitivity of 
the method, ease of sample preparation, time consumption 
and the solubility of the drug. CPF is practically insoluble 
in water, freely soluble in anhydrous ethanol and soluble 
in toluene (European Pharmacopeia, 2008). The use of 
acetonitrile, methanol or sodium hydroxide (0.1 and 
0.01 M) as the diluent did not improve the sensitivity of 
the method. Thus, anhydrous ethanol was tested as the 
solvent, after addition of distilled water, in order to reduce 
organic solvent use. Absorption spectra were obtained by 
UV spectrophotometry in the range of 200-400 nm for the 
standard solutions in various solvents, and the overlap is 
shown in Figure 4.
The final decision to use ethanol and water as the 
analysis medium was based on various criteria, including 
the sensitivity of the method, cost, ease of preparation and 
the accuracy of the results.
Method validation
The validation ensures that the procedure is suitable 
for the intended purpose. The ICH and USP guidelines 
describe the analytical parameters that should be evaluated 
in a method validation. The method type and its intended 
use determine which parameters should be evaluated. It 
is the responsibility of the analyst to select the parameters 
that are considered to be relevant for each method (Ermer, 
2001). The LC and UV spectrophotometric methods were 
validated for parameters such as linearity, specificity, 
precision, accuracy and robustness.
Linearity was established by least-squares linear 
regression analysis of the calibration curve. The regression 
equation for CPF was found by plotting the peak 
absorbance (y) versus the sample concentration (x). 
Correlation coefficients of 0.9999 (for the LC method) 
and 0.9998 (for the UV method) were considered to be 
FIGURE 4. Overlap of the absorption spectra obtained by UV spectrophotometry in the range of 200-400 nm, of the standard 
solutions in: a) ethanol and water (diluent); b) sodium hydroxide 0.01M; c) sodium hydroxide 0.1M; d) methanol; e) acetonitrile 
and f) ethanol.
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TABLE I - Linearity data for UV and LC analyses
LC UV
Correlation coefficient 0.9999 0.9998
Linear equation y = 49069x – 17753 y = 0.0462x – 0.0282
Linear regression* Fcalculated = 22746 > Fcritical = 4.96 Fcalculated = 17081 > Fcritical = 4.96
Linearity deviation* Fcalculated = 1.4 < Fcritical = 3.71 Fcalculated = 2.4 < Fcritical = 3.71
* p < 0.05
TABLE II - Results of CPF stability under force degradation conditions and regular conditions
Condition Time (h) Degradation (%)
Acid hydrolysis (1 N HCl) 4 60.47
Basic hydrolysis (1 M NaOH) 7 70.87
Oxidation (H2O2) 3 60.14
Photolysis 1.5 55.64
Regular conditions (ethanol:water, room temperature)
2
no degradation
6
8
24
highly significant. The validity of the assays was verified 
by means of ANOVA analysis (SAS 6.11 for windows, 
SAS Institute Inc. CARY, NC, USA), which demonstrated 
significant linear regression and no significant linearity 
deviation (Table I).
The specificity test demonstrated that there was no 
interference in the UV spectrophotometric determination 
of the drug. All solutions were scanned from 400 to 
200 nm and checked for any change in the absorbance at 
the respective wavelengths. The UV spectrophotometric 
method proves to be specific for the determination of drugs 
present in tablet and capsule matrices, because there is 
no interference caused by excipients at the wavelength 
of the drug maximum absorption (λmax 233). Forced 
degradation studies for the determination of the specificity 
of the direct UV method were not performed. Owing to 
specificity/selectivity limitations (e.g., in general terms, 
the degradation products present functional groups that 
absorb at the same wavelength of the intact drug), there are 
very few reports on the use of UV spectrophotometry for 
stability assays. However, there are some reports involving 
derivative spectroscopy that have been published 
recently (Abbas et al., 2012; Cielecka-Piontek, Lunzer, 
Jelińska, 2011). LC methods have taken precedence over 
conventional analysis methods; reverse-phase LC coupled 
with ionic suppression probably accounts for over 85% 
of stability-indicating methodologies for low-molecular-
weight pharmaceutical entities. Other than the separation 
of multiple components, the advantage of LC methods is 
that they possess greater accuracy and sensitivity for even 
small quantities of degradation products (Bakshi, Singh, 
2002; Shabir, 2003).
The forced degradation studies were conducted to 
evaluate the stability-indicating capability and selectivity 
of the proposed LC method using the CPF reference 
substance. Table II presents the extent of CPF degradation 
under both stress conditions and regular conditions, and 
Figure 5 shows the chromatograms of the untreated 
solution and the forced degradation samples.
It is important to note that although several 
degradation product peaks can be observed, the peak for 
CPF remains resolved. The chromatographic peak purity 
tool was applied to verify the CPF peak, showing that it 
was 100% pure in all cases, indicating the specificity of 
the proposed method. It was observed that the CPF peak 
presents appropriate resolution (Rs > 2) and selectivity 
(a > 1) in relation to the degradation products. The results 
indicated that the method is indeed stability-indicating 
and that the drug can be evaluated both qualitatively and 
quantitatively in the presence of degradation products. 
The obtained results in the forced degradation studies 
show that the drug is susceptible to hydrolysis, oxidation 
and photolysis. Therefore, the stability of CPF in 
anhydrous ethanol and water was evaluated to verify if 
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FIGURE 5 - a) Typical chromatogram for 20.0 µg mL-1 CPF standard solution in the experimental selected conditions; 
b) chromatogram of CPF acid-degraded and degradation product A1 and A2; c) chromatogram of CPF basic-degraded and 
degradation products B1, B2, B3, B4 and B5; d) chromatogram of CPF oxidative-degraded and degradation product.
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any spontaneous degradation could occur between sample 
preparation and analysis. The data obtained showed that 
sample solutions were stable for at least 24 h when stored 
at room temperature (Table II).
The precision of the methods was determined by 
studying the repeatability and the intermediate precision. 
The experimental values obtained for the quantification 
of CPF in various samples are presented in Table III. The 
variability of the results was low, with RSD% values less 
than 1.8 for repeatability and 1.4 for intermediate-precision 
analysis. The RSD% values that were obtained for the 
analytical methods were within the acceptable range, 
indicating that these methods have great repeatability and 
intermediate precision.
With regards to the accuracy of the two methods, 
the excellent mean percentage recovery values and 
their low RSD% (≤ 1.5) were found to be satisfactory. 
At each CPF concentration, three determinations were 
performed for each method. The mean recovery for the UV 
spectrophotometric method was 99.15% (RSD% = 0.81) 
and 102.59% (RSD% = 0.77) for the tablets and capsules, 
respectively, and the LC mean recovery was 100.54% 
(RSD% = 1.15) and 99.64% (RSD% = 1.44). These results 
revealed that any small change in drug concentration in 
these solutions could be accurately determined by the 
proposed analytical methods.
The robustness of each method was demonstrated 
by small variations in the analytical conditions, which 
are cited above. The obtained results (Table IV) show that 
there are no important effects on the analysis, confirming 
the robustness of the proposed methods.
Comparison of the UV spectrophotometric 
method and the LC method
The analytical methods were compared using 
statistical analysis. The two one-sided test (TOST) 
(XLSTAT Version 2014.1.07 for windows) was used as 
an equivalence test to compare the experimental values 
TABLE III - LC and UV assay precision results for CPF in tablets 
and capsules
Tablets 
mean ± RSD%
Capsules 
mean ± RSD%
LC
1 day (n=6) 102.54 ± 1.20 97.90 ± 1.03
2 day (n=6) 100.73 ± 0.74 98.67 ± 0.61
3 day (n=6) 99.62 ± 1.76 98.89 ± 1.59
Inter-daya 100.96 ± 1.13 98.49 ± 0.43
UV
1 day (n=6) 102.41 ± 0.78 99.83 ± 0.56
2 day (n=6) 100.52 ± 0.50 96.84 ± 0.83
3 day (n=6) 100.44 ± 0.69 97.32 ± 0.25
Inter-daya 101.12 ± 0.90 98.00 ± 1.31
a Data expressed as the mean of 3 days.
TABLE IV - Experimental values for the robustness testing, obtained from UV and LC analysis of CPF in tablets and capsules
Analysis conditions
CPF content
Tablets  
mean* ± RSD%
Capsules  
mean* ± RSD%
LC
Column (different supplier) 
Temperature 30 °C
Flow rate 0.8 mL min-1
Flow rate 1.2 mL min-1
70% acetonitrile
60% acetonitrile
pH 2.7
pH 3.3
Regular conditions
98.75 ± 0.67
102.91 ± 2.28
98.86 ± 0.59
101.28 ± 1.12
99.16 ± 0.38
99.16 ± 0.38
99.26 ± 0.31
98.72 ± 0.69
99.70 ± 0.86
95.78 ± 0.58
96.87 ± 0.22
95.72 ± 0.62
97.76 ± 0.87
95.43 ± 0.83
95.28 ± 0.94
95.43 ± 0.83
94.93 ± 1.20
96.57 ± 0.77
UV
Addition of 8 mL ethanol
Addition of 15 mL ethanol
Sonication for 3 min
Sonication for 7 min
24 h at room temperature (25 °C)
Different ethanol manufacturer
Regular conditions
100.27 ± 0.90
99.92 ± 1.70
101.18 ± 0.30
101.37 ± 0.37
101.71 ± 0.48
100.32 ± 0.54
100.04 ± 0.71
98.65 ± 0.42
99.99 ± 0.53
98.27 ± 0.43
99.06 ± 0.56
98.58 ± 0.47
99.69 ± 0.73
99.00 ± 0.16
*n = 3
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TABLE V - TOST results for the comparison of the LC and UV methods
CPF in tablets CPF in capsules
Test Value Test Value
Lower bound (TOST) -2.000 Lower bound (TOST) -2.000
Lower bound (90%) -0.703 Lower bound (90%) -0.296
Upper bound (90%) 1.021 Upper bound (90%) 1.276
Upper bound (TOST) 2.000 Upper bound (TOST) 2.000
Test interpretation equivalent Test interpretation equivalent
α = 0.05
(Table III) that were obtained from the analysis of samples 
with the two different methods. Equivalence was tested 
by determining 90% confidence intervals, based on 
the experimental values obtained in the precision test. 
We could accept the null hypothesis and declare that 
the analytical methods were equivalent when the 90% 
confidence interval for the difference was completely 
contained within the defined range considered to be 
scientifically trivial (± ∆). We defined ∆ = 2 as an 
appropriate range for the equivalence testing, based on the 
specifications of the precision test (RSD% ≤ 2). TOST was 
applied and showed equivalence, at the 5% significance 
level, between the experimental values obtained in the 
sample analysis when using the different methods, as 
shown in Table V.
The developed and validated methods provide 
similar results for CPF quantitation, and can be 
applied directly and easily to oral preparations of the 
pharmaceutical drug. The direct UV method is a useful 
tool for routine analysis, but when it is necessary to prove 
the stability and to identify and/or quantify the degradation 
products, the chromatographic methods are a better choice, 
owing to the stability-indicating capability and superior 
sensitivity and selectivity. However, the time and cost of 
the analyses cannot be disregarded in routine analysis, and 
the spectrophotometric method is clearly less expensive, 
easier to use, requires a shorter analysis time and generates 
fewer residues.
CONCLUSION
This study presents two simple methods for the 
determination and quantification of CPF in pharmaceutical 
formulations. The methods were validated, showing 
satisfactory data for all of the tested parameters. There 
were no significant differences between the stability-
indicating LC and UV spectrophotometric methods. As 
both of these methods are fast and simple, they may be 
successfully applied to quality-control analyses, with the 
aim of quantifying and identifying CPF in pharmaceutical 
products.
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